UB Paderborn / Katalog / Suche / in CDI

Exploitation of eukaryotic subcellular targeting mechanisms by bacterial effectors

Nature reviews. Microbiology, 2013-05, Vol.11 (5), p.316-326

2013

Link zum Volltext

Verfügbarkeit prüfen

family of Salmonella virulence factors functions as a distinct class of autoregulated E3 ubiquitin ligases

Proceedings of the National Academy of Sciences - PNAS, 2009-03, Vol.106 (12), p.4864-4869

2009

Link zum Volltext

Verfügbarkeit prüfen

Subcellular targeting of Salmonella virulence proteins by host-mediated S-palmitoylation

Cell host & microbe, 2011-07, Vol.10 (1), p.9-20

2011

Link zum Volltext

Verfügbarkeit prüfen

Golgi structure in stress sensing and apoptosis

Biochimica et biophysica acta, 2005-07, Vol.1744 (3), p.406-414

2005

Link zum Volltext

Verfügbarkeit prüfen

The Antitumor Activity of IMGN529, a CD37-Targeting Antibody-Drug Conjugate, Is Potentiated by Rituximab in Non-Hodgkin Lymphoma Models

Neoplasia (New York, N.Y.), 2017-09, Vol.19 (9), p.661-671

2017

Link zum Volltext

Verfügbarkeit prüfen

Hijacking the host ubiquitin pathway: structural strategies of bacterial E3 ubiquitin ligases

Current opinion in microbiology, 2010-02, Vol.13 (1), p.41-46

2010

Link zum Volltext

Verfügbarkeit prüfen

Golgin-160 is required for the Golgi membrane sorting of the insulin-responsive glucose transporter GLUT4 in adipocytes

Molecular biology of the cell, 2006-12, Vol.17 (12), p.5346-5355

2006

Link zum Volltext

Verfügbarkeit prüfen

Isoform-specific Interaction of Golgin-160 with the Golgi-associated Protein PIST

The Journal of biological chemistry, 2005-08, Vol.280 (32), p.28944-28951

2005

Link zum Volltext

Verfügbarkeit prüfen

GCP60 Preferentially Interacts with a Caspase-generated Golgin-160 Fragment

The Journal of biological chemistry, 2006-09, Vol.281 (38), p.27924-27931

2006

Link zum Volltext

Verfügbarkeit prüfen

The NH2-terminal Domain of Golgin-160 Contains Both Golgi and Nuclear Targeting Information

The Journal of biological chemistry, 2002-09, Vol.277 (39), p.35833-35839

2002

Link zum Volltext

Verfügbarkeit prüfen

Differential Regulation of Two Palmitoylation Sites in the Cytoplasmic Tail of the β1-Adrenergic Receptor

The Journal of biological chemistry, 2011-05, Vol.286 (21), p.19014-19023

2011

Link zum Volltext

Verfügbarkeit prüfen

Microscale screening of antibody libraries as maytansinoid antibody-drug conjugates

mAbs, 2016-04, Vol.8 (3), p.513-523

2016

Link zum Volltext

Verfügbarkeit prüfen

Death from within: apoptosis and the secretory pathway

Current opinion in cell biology, 2003-08, Vol.15 (4), p.456-461

2003

Link zum Volltext

Verfügbarkeit prüfen

Golgin‐160 Promotes Cell Surface Expression of the Beta‐1 Adrenergic Receptor

Traffic (Copenhagen, Denmark), 2006-12, Vol.7 (12), p.1666-1677

2006

Link zum Volltext

Verfügbarkeit prüfen

Non-viral adeno-associated virus-based platform for stable expression of antibody combination therapeutics: Non-viral adeno-associated virus-based platform for stable expression of antibody combination therapeutics

mAbs, 2014-07, Vol.6 (4), p.957-967

2014

Link zum Volltext

Verfügbarkeit prüfen

Abstract 4817: Preclinical evaluation of a new, non-agonist ADC targeting MET -amplified tumors with a peptide-linked maytansinoid

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.4817-4817

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1841: IMGC936, an investigational ADAM9-targeting antibody drug conjugate, is active against patient-derived ADAM9-expressing xenograft models

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.1841-1841

2021

Link zum Volltext

Verfügbarkeit prüfen

Abstract 219: The potential benefit of lower drug-antibody ratio (DAR) on antibody-maytansinoid conjugate in vivo efficacy

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.219-219

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1073: Increased internalization and processing of the CD37-targeting antibody-drug conjugate, naratuximab emtansine (IMGN529), in the presence of rituximab leads to enhanced potency in diffuse large B-cell lymphoma models

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.1073-1073

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract 45: In vitro and in vivo activity of a novel c-Met-targeting antibody-drug conjugate using a DNA-alkylating, indolinobenzodiazepine payload

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.45-45

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract 213: Development of a probody-drug conjugate targeting EpCAM for the treatment of solid tumors

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.213-213

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract 37: Novel antibody-drug conjugates targeting ADAM9-expressing solid tumors demonstrate potent preclinical activity

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.37-37

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract 38: Target validation, antibody discovery and preclinical data supporting ADAM9 as an antibody-drug conjugate therapeutic target for solid tumors

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.38-38

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract 5442: Microscale methods for preparation and screening of antibody-drug conjugates

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.5442-5442

2015

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Exploitation of eukaryotic subcellular targeting mechanisms by bacterial effectors

family of Salmonella virulence factors functions as a distinct class of autoregulated E3 ubiquitin ligases

Subcellular targeting of Salmonella virulence proteins by host-mediated S-palmitoylation

Golgi structure in stress sensing and apoptosis

The Antitumor Activity of IMGN529, a CD37-Targeting Antibody-Drug Conjugate, Is Potentiated by Rituximab in Non-Hodgkin Lymphoma Models

Hijacking the host ubiquitin pathway: structural strategies of bacterial E3 ubiquitin ligases

Golgin-160 is required for the Golgi membrane sorting of the insulin-responsive glucose transporter GLUT4 in adipocytes

Isoform-specific Interaction of Golgin-160 with the Golgi-associated Protein PIST

GCP60 Preferentially Interacts with a Caspase-generated Golgin-160 Fragment

The NH2-terminal Domain of Golgin-160 Contains Both Golgi and Nuclear Targeting Information

Preclinical Evaluation of IMGC936, a Next Generation Maytansinoid-based Antibody-drug Conjugate Targeting ADAM9-expressing Tumors

Differential Regulation of Two Palmitoylation Sites in the Cytoplasmic Tail of the β1-Adrenergic Receptor

Microscale screening of antibody libraries as maytansinoid antibody-drug conjugates

Death from within: apoptosis and the secretory pathway

Golgin‐160 Promotes Cell Surface Expression of the Beta‐1 Adrenergic Receptor

Non-viral adeno-associated virus-based platform for stable expression of antibody combination therapeutics: Non-viral adeno-associated virus-based platform for stable expression of antibody combination therapeutics

Abstract 4817: Preclinical evaluation of a new, non-agonist ADC targeting MET -amplified tumors with a peptide-linked maytansinoid

Abstract 1841: IMGC936, an investigational ADAM9-targeting antibody drug conjugate, is active against patient-derived ADAM9-expressing xenograft models

Abstract 219: The potential benefit of lower drug-antibody ratio (DAR) on antibody-maytansinoid conjugate in vivo efficacy

Abstract 1073: Increased internalization and processing of the CD37-targeting antibody-drug conjugate, naratuximab emtansine (IMGN529), in the presence of rituximab leads to enhanced potency in diffuse large B-cell lymphoma models

Abstract 45: In vitro and in vivo activity of a novel c-Met-targeting antibody-drug conjugate using a DNA-alkylating, indolinobenzodiazepine payload

Abstract 213: Development of a probody-drug conjugate targeting EpCAM for the treatment of solid tumors

Abstract 37: Novel antibody-drug conjugates targeting ADAM9-expressing solid tumors demonstrate potent preclinical activity

Abstract 38: Target validation, antibody discovery and preclinical data supporting ADAM9 as an antibody-drug conjugate therapeutic target for solid tumors

Abstract 5442: Microscale methods for preparation and screening of antibody-drug conjugates

Suchergebnisse filtern